CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0897 (clinicaltrials.gov NCT No: NCT01980654)
Title:A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab in Previously Untreated Subjects with
Follicular Lymphoma
Principal Investigator:Nathan Fowler
Treatment Agent:Ibrutinib; Rituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
ibrutinib (IMBRUVICA ®) and rituximab can help control FL. The
safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Ibrutinib
Rituximab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics, Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults